Abstract:Dapagliflozin (trade name FARXIGA) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has transcended its initial antidiabetic application to demonstrate benefits in cardiac and renal diseases. It was first approved by the food and department administration for type 2 diabetes in 2014. Since then, it has gained food and department administration approval for chronic kidney disease in 2021, heart failure with reduced ejection fraction in 2020, and heart failure with preserved ejection fraction in 2023. Thus, dapagliflozin plays a pivotal role in improving patient outcomes. By competitive binding to renal SGLT-2 cotransporters, dapagliflozin effectively prevents glucose and sodium reabsorption, leading to glucosuria. Its pharmacokinetic profile involves minimal cytochrome P450-induced metabolism, rapid absorption with an 18-hour duration of action, and stable effects. Clinical trials have revealed dapagliflozin's efficacy in glycemic control without the risk of hypoglycemia, making it an advantageous choice for patients insufficiently managed on other antidiabetic drugs. Comparative analysis with other SGLT-2 inhibitors suggests dapagliflozin's potential superiority in preventing heart failure. Compared to empagliflozin, it has more extended effects, contributing to stable sodium diuresis, reduced blood pressure fluctuations, and potentially lower cardiovascular disease risks. However, it leads to less urinary glucose excretion compared with canagliflozin. Dapagliflozin has specific contraindications, such as type 1 diabetes and end-stage chronic kidney disease. Adverse effects include an increased risk of genital infections, urinary tract infections, and Fournier's gangrene. A nuanced understanding of dapagliflozin's benefits and limitations is imperative for informed clinical decision-making in the management of diabetes and its complications.

Dapagliflozin, a Novel Sodium-Glucose Transporter 2 Inhibitor in Treatment of Type 2 Diabetes

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

SGLT2 Inhibitors: a New Therapy for Diabetes

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (sglt2) Inhibitor for the Treatment of Type 2 Diabetes

SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

Dapagliflozin: a review on efficacy, clinical effectiveness and safety

SGLT2i: beyond the glucose-lowering effect

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus

Sodium-glucose Cotransporter-2 Inhibitors: Current Knowledge on the Use of Canagliflozin, Dapagliflozin and Empagliflozin in the Treatment of Type 2 Diabetes Mellitus

Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus

Research on Type 2 Sodium Glucose Co-Transporters in Diabetes Treatment

Recent Progress of Sodium-Glucose Transporter 2 Inhibitors As Potential Antidiabetic Agents.

Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus.

Dapagliflozin: Glucuretic action and beyond

SGLT2 inhibitors in the management of type 2 diabetes

Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

Dapagliflozin efficacy and safety: a perspective review

SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus

SGLT-2 Inhibitors: Focus on Dapagliflozin